Background
Endometriosis is a chronic, estrogen-dependent inflammatory disorder that affects a significant proportion of women
of reproductive age. Although the pathophysiology of the disease remains incompletely understood, genetic and hormonal factors
are believed to play key roles. T wo genes of particular interest in this context are Estrogen Receptor 1 (ESR1) and Growth Regulation
by Estrogen in Breast Cancer 1 (GREB1), both of which are integral to estrogen signaling and cell proliferation. This study aimed to
investigate the potential contribution of missense Single Nucleotide Polymorphisms (SNPs) in the ESR1 and GREB1 genes to the
pathogenesis of endometriosis using an in silico approach.
Materials and methods
Publicly available data from National Center for Biotechnology Information and SNP database were used to
identify missense variants in ESR1 and GREB1. The functional impact of each variant was predicted using six bioinformatics tools:
Sorting Intolerant From T olerant, Polymorphism Phenotyping v2, Protein Variation Effect Analyzer, SNPs and Gene Ontology, Protein
Analysis Through Evolutionary Relationships, and PredictSNP . Protein-protein interaction networks were constructed via the Search
T ool for the Retrieval of Interacting Genes/Proteins and Gene Multiple Association Network Integration Algorithm platforms, and
disease and pathway associations were analyzed using the Kyoto Encyclopedia of Genes and Genomes and DISEASES databases.
Results
ESR1 was found to be a central node in estrogen signaling, with strong predicted interactions with GREB1 and other
hormone-regulated genes. Several SNPs in both genes were consistently classified as deleterious across all predictive tools. Disease
enrichment analysis further linked these genes to endometriosis, as well as to other estrogen-responsive conditions such as breast
and ovarian cancers.
Conclusion
This study identifies potentially high-risk ESR1 and GREB1 variants and highlights their involvement in key estrogen-
regulated pathways. These findings support the role of genetic variation in the molecular pathogenesis of endometriosis and lay the
groundwork for future experimental validation.
Keywords
GREB1, ESR1, in silico, endometriosis, immunoinformatics
Amaç: Endometriozis, üreme çağındaki kadınların önemli bir kısmını etkileyen, kronik ve östrojene bağımlı enflamatuvar bir
hastalıktır. Hastalığın patofizyolojisi tam olarak aydınlatılamamış olmakla birlikte, genetik ve hormonal faktörlerin önemli rol
oynadığı düşünülmektedir. Bu bağlamda özellikle dikkat çeken iki gen, östrojen sinyal iletimi ve hücre proliferasyonu açısından
kritik olan Östrojen Reseptörü 1 (ESR1) ve Meme Kanserinde Östrojenle Düzenlenen Büyüme Geni 1’dir (GREB1). Bu çalışma, in silico bir
yaklaşımla ESR1 ve GREB1 genlerindeki anlamsal (missense) T ek Nükleotid Polimorfizmlerinin (SNP’ler) endometriozis patogenezine
olası katkısını araştırmayı amaçlamıştır.
Gereç ve Yöntemler: ESR1 ve GREB1 genlerindeki anlamsal varyantları belirlemek için Ulusal Biyoteknoloji Bilgi Merkezi ve T ek
Nükleotid Polimorfizmi Veri Tabanı gibi halka açık veri tabanları kullanılmıştır. Her bir varyantın fonksiyonel etkisi; T olere Edilemeyen
Değişiklikleri Ayırma Aracı, Polimorfizm Fenotipleme Aracı, Versiyon 2, Protein Varyasyonu Etki Analizörü, SNPs ve Gen Ontolojisi Aracı,
Evrimsel İlişkiler Üzerinden Protein Analizi ve PredictSNP olmak üzere altı farklı biyoinformatik aracıyla tahmin edilmiştir. Protein-
ABSTRACTÖZ
DOI: 10.4274/hamidiyemedj.galenos.2025.98698
Introduction
Endometriosis is a chronic, estrogen-dependent
inflammatory disorder characterized by the presence of
functional endometrial tissue outside the uterine cavity.
Although the ectopic endometrial lesions are most frequently
located within the pelvic region, affecting structures such
as the ovaries, pouch of Douglas, sacrouterine ligaments,
pelvic peritoneum, rectovaginal septum, and cervix,
there are documented cases of extra-pelvic involvement.
Rarely, a comma is included endometriotic foci have been
identified in organs including the lungs, pleura, diaphragm,
intestines, gallbladder, kidneys, ureters, umbilicus, skin,
central nervous system, and extremities (1,2).
The prevalence of endometriosis among women of
reproductive age ranges from 3% to 37%, and despite
its high frequency and significant impact on quality of
life and fertility, the pathogenesis of the disease remains
incompletely understood (3). One of the major contributing
factors to this knowledge gap is the complex nature
of its genetic background. Current evidence suggests a
polygenic and multifactorial inheritance pattern, wherein
disease development results from a combination of genetic
predisposition and environmental influences (4).
Identifying specific genetic contributors is complicated
by several factors. The necessity for invasive procedures,
such as laparoscopy or laparotomy, for definitive diagnosis
limits early detection and may result in underdiagnosis (5).
Furthermore, endometriosis is now considered a
heterogeneous condition encompassing multiple
subtypes such as superficial peritoneal lesions, ovarian
endometriomas, and deeply infiltrating endometriosis,
each with potentially distinct genetic and molecular
characteristics. Environmental exposures, particularly to
endocrine-disrupting chemicals like dioxins, may further
influence disease development and expression (6,7).
In this study, the investigation of genes such as Estrogen
Receptor 1 (ESR1) and Growth Regulation by Estrogen in
Breast Cancer 1 (GREB1) has gained attention due to their
pivotal roles in estrogen signaling, cell proliferation, and
endometrial receptivity, all of which are relevant in the
etiology and progression of endometriosis (7-11). This study
aims to explore the potential contribution of missense
Single Nucleotide Polymorphisms (SNPs) in the ESR1 and
GREB1 genes to the pathogenesis of endometriosis using
a comprehensive in silico bioinformatics approach. By
evaluating the functional impact of these genetic variants,
mapping protein-protein interactions (PPIs), and analyzing
disease-associated pathways, we seek to identify high-risk
mutations and elucidate possible molecular mechanisms
through which these genes may influence the development
and progression of endometriosis.
Materials and methods
Retrieval of Protein Sequences and Missense Variants for
ESR1 and GREB1 Genes
Publicly available data from the National Center for
Biotechnology Information (NCBI) and the NCBI Single
Nucleotide Polymorphism database (dbSNP) were used to
investigate the ESR1 and GREB1 genes associated with
endometriosis. Protein sequences and known SNPs for
both genes were retrieved and analyzed. The focus was
on missense mutations, as these variants result in amino
acid changes that may alter the protein’s structure and
impair its normal biological function. Such changes can
affect processes like hormone binding or gene regulation,
which are critical in the pathogenesis of endometriosis.
Bioinformatics tools were then applied to evaluate the
potential effects of these mutations on protein function
(12,13).
Interaction Analysis of GREB1 and ESR1
T o explore the functional and physical interactions
involving the GREB1 and ESR1 genes, the Search T ool for the
Retrieval of Interacting Genes/Proteins (STRING) database
Özbey and Kırkık. ESR1 and GREB1 Variants in Endometriosis
protein etkileşim ağları etkileşimli gen/proteinleri bulma aracı ve gen çoklu ilişki ağlarını entegre etme algoritması platformları
aracılığıyla oluşturulmuş, hastalık ve yolak ilişkileri Kyoto genler ve genomlar ansiklopedisi ve DISEASES veri tabanı kullanılarak
analiz edilmiştir.
Bulgular: ESR1’nin, östrojen sinyal yolaklarında merkezi bir düğüm olduğu ve GREB1 ile diğer hormonla düzenlenen genlerle
güçlü etkileşimler gösterdiği tespit edilmiştir. Her iki gendeki bazı SNP’ler, tüm tahmin araçlarında tutarlı şekilde zararlı olarak
sınıflandırılmıştır. Hastalık zenginleştirme analizleri, bu genleri endometriozis ile birlikte meme ve over kanseri gibi diğer östrojen
duyarlı hastalıklarla da ilişkilendirmiştir.
Sonuç: Bu çalışma, ESR1 ve GREB1 genlerindeki potansiyel yüksek riskli varyantları ortaya koymuş ve bu genlerin östrojenle
düzenlenen temel yolaklardaki rolüne dikkat çekmiştir. Bulgular, genetik varyasyonların endometriozisin moleküler patogenezindeki
rolünü desteklemekte ve ileri deneysel doğrulama çalışmaları için bir temel oluşturmaktadır.
Anahtar Kelimeler: GREB1, ESR1, in silico, endometriozis, immünoinformatik
ÖZ
(version 11.5) was employed using a medium confidence
interaction score threshold (≥0.4). This platform was used
to build a comprehensive PPI network and to predict
associations based on known and predicted interactions. In
parallel, the Gene Multiple Association Network Integration
Algorithm (GeneMANIA) tool (version 3.5.2) was used to
further investigate gene-gene relationships and to identify
additional genes functionally linked to GREB1 and ESR1.
This analysis included co-expression, shared pathways,
co-localization, and physical interaction data. The results
obtained from GeneMANIA were cross-referenced with the
STRING analysis to confirm the consistency and biological
relevance of the predicted interactions. All computational
analyses were conducted between February 2 and 8, 2025,
ensuring up-to-date and reliable data integration (14,15).
Identifying the Most Deleterious SNPs
T o assess the potential functional consequences of
non-synonymous SNPs identified in the ESR1 and GREB1
genes, six independent in silico prediction tools were
employed: Sorting Intolerant From T olerant (SIFT) (https://
sift.jcvi.org), Protein ANalysis THrough Evolutionary
Relationships (PANTHER) (https://www.pantherdb.org/
tools), Polymorphism Phenotyping v2 (PolyPhen-2) (https://
genetics.bwh.harvard.edu/pph2/), SNPs&Gene Ontology
(GO) (https://snps.biofold.org/snps-and-go/), Protein
Variation Effect Analyzer (PROVEAN) (https://provean.
jcvi.org), and PredictSNP (https://loschmidt.chemi.muni.
cz/predictsnp). These tools were used to evaluate the
likelihood of deleterious effects caused by each amino acid
substitution. Variants that were consistently classified as
damaging by all six tools were considered to be high-risk
mutations with strong potential to impair protein function.
Each tool applies a different algorithm to determine the
pathogenicity of SNPs. SIFT utilizes sequence homology
to determine whether an amino acid change is tolerated,
flagging substitutions with a probability score below
0.05 as deleterious. PANTHER evaluates evolutionary
conservation and functional domains to estimate the effect
of substitutions. PolyPhen-2 predicts the potential structural
and functional consequences of amino acid changes based
on multiple sequence alignments and protein structure
features. SNPs&GO integrates gene ontology data with
machine learning (support vector machine-based) models
to associate mutations with disease. PROVEAN applies a
sequence-based approach to assess whether amino acid
substitutions are functionally disruptive, using a cutoff
score of -2.5 to classify variants. Lastly, PredictSNP combines
predictions from several algorithms (including SIFT,
PolyPhen-2, Multivariate Analysis of Protein Polymorphism,
Screening for Non-Acceptable Polymorphisms, and Predictor
of Human Deleterious-SNP) to generate a consensus
assessment of each SNP’s deleterious potential.
Pathway and Disease Association Analysis of GREB1 and
ESR1
Pathway and disease analyses for the GREB1 and ESR1
genes were performed using the Kyoto Encyclopedia of
Genes and Genomes (KEGG) database to explore their
roles in essential molecular pathways, particularly those
associated with hormone signaling and estrogen-responsive
mechanisms relevant to endometriosis. Access to the KEGG
pathway data was facilitated through the KEGG application
programming interface, allowing systematic mapping of
gene functions in biological processes such as estrogen
signaling, cell proliferation, and transcriptional regulation.
T o complement these findings, disease associations were
extracted from the DISEASES database (JensenLab, 2024
version), which provided insight into the clinical relevance
of GREB1 and ESR1 in endometriosis and other hormone-
related disorders. Additionally, the STRING database was
used to construct PPI networks, further validating the
involvement of these genes in interconnected regulatory
systems. This integrated bioinformatics approach revealed
key functional pathways and disease links associated with
GREB1 and ESR1 (16-18).
Statistical Analysis
All bioinformatics and in silico statistical analyses
were conducted using integrated online platforms and
computational tools. Functional predictions of missense
variants were obtained from SIFT, PolyPhen-2, PROVEAN,
PANTHER, SNPs&GO, and PredictSNP web servers. Protein-
protein interaction networks were analyzed via STRING
(version 11.5; European Molecular Biology Laboratory,
Heidelberg, Germany) and GeneMANIA (version 3.5.2;
University of T oronto, T oronto, Canada). Pathway and
disease enrichment analyses were performed using the
KEGG database (KEGG, Kyoto University, Kyoto, Japan) and
DISEASES database (JensenLab, Copenhagen, Denmark). All
analyses were performed between February 2 and February
10, 2025, and descriptive statistics were automatically
calculated by the respective bioinformatics servers.
Results
Identifying the Most Deleterious SNPs
Although this study primarily focused on missense
variants, all listed GREB1 SNPs are intronic and were
included due to their potential regulatory relevance
as supported by prior literature. These variants were
therefore excluded from functional prediction analyses.
Özbey and Kırkık. ESR1 and GREB1 Variants in Endometriosis
The initial step of our analysis involved the identification
and curation of SNPs within the GREB1 and ESR1 genes,
both of which are implicated in estrogen signaling and
have been associated with hormone-dependent conditions
including endometriosis. Table 1 presents the complete list
of selected variants, annotated with reference SNP cluster
IDs, allelic composition, ancestral alleles, Human Genome
Variation Society nomenclature-compliant transcript-based
nomenclature, chromosomal positions, and minor allele
frequencies (MAFs). Importantly, all variants listed under
ESR1 are exonic and classified as missense mutations,
thus, eligible for functional prediction analysis via in silico
tools such as SIFT, PolyPhen-2, and PROVEAN. In contrast,
all GREB1 variants in our dataset are located in intronic
regions, rendering them non-coding and thereby outside the
scope of classical missense-based prediction algorithms.
Nevertheless, these GREB1 variants were retained due to
their high population frequency and potential regulatory
roles, as suggested by previous genome-wide association
and transcriptomic studies linking GREB1 expression to
estrogen-mediated proliferation in endometrial tissues.
Among the ESR1 variants, rs753014570 (c.728G>A)
and rs779180038 (c.727C>T) occur in close proximity
within the coding sequence, possibly affecting the same
functional domain, and may act in tandem as a multi-
nucleotide polymorphism in certain haplotypes. Variant
rs773500294 also appears as a duplicated entry in public
databases, with different reported alternative alleles (C>A
and C>G), which requires cautious interpretation due to
possible annotation inconsistencies. The low MAFs (<0.01)
of several ESR1 variants suggest they may represent
rare, potentially pathogenic alterations with relevance to
disease susceptibility. These prioritized SNPs served as the
foundation for downstream analyses, including PPI mapping
and disease association profiling.
Interaction Analysis of GREB1 and ESR1
PPI analysis revealed that ESR1 occupies a central
position within the interaction network, engaging in
numerous functional associations with other proteins
relevant to estrogen signaling and transcriptional regulation.
Notably, GREB1 and its paralog GREB1L demonstrated
strong connectivity with ESR1, supporting their known
roles as estrogen-responsive genes. The presence of thick
interaction lines indicates high-confidence associations,
suggesting a direct regulatory relationship. Similarly, a
prominent interaction was observed between ESR1 and
progesterone receptor (PGR), highlighting the interplay
between estrogen and progesterone pathways in hormone-
regulated tissues (Figure 1).
The corresponding interaction network is presented
in Figure 1. In the GeneMANIA-derived visualization,
different edge colors represent distinct types of functional
associations: pink lines indicate co-expression, blue lines
denote physical interactions, green lines correspond to co-
localization, and orange lines reflect predicted interactions.
These integrated networks provide evidence for the
functional linkage between ESR1 and GREB1, particularly
within estrogen-responsive signaling pathways.
Disease association analysis performed using the
Özbey and Kırkık. ESR1 and GREB1 Variants in Endometriosis
Table 1. Summary of selected SNPs in ESR1 and GREB1 genes, including their HGVS nomenclature, genomic location, ancestral and
alternative alleles, and MAF. All GREB1 variants listed are intronic and not eligible for functional prediction via missense-specific tools
Source rs ID Allele Ancestral HGVS name Location MAF
GREB1
rs13394619 A/G A ENST00000234142.9: c.1160-1365G>A Chromosome 2:11587381 0.50
rs11674184 A/T T ENST00000234142.9: c.901+577T>A Chromosome 2:11581409 0.37
rs12470971 A/G G ENST00000234142.9: c.902-46G>A Chromosome 2:11585115 0.50
rs11686574 C/G C ENST00000381483.6: c.-159+1064C>G Chromosome 2:11543881 0.47
rs6740248 C/G C ENST00000234142.9: c.454+110C>G Chromosome 2:11566766 0.22
rs2930961 C/T T ENST00000336148.10: c.305-20263A>G Chromosome 8:94431578 0.40
rs1250248 A/G G ENST00000323926.10: c.1394-127T>C Chromosome 2:215422370 0.22
ESR1
rs139960913 C/T C ENST00000206249.8: c.16C>T Chromosome 6:151807928 0.01
rs746521050 G/A G ENST00000206249.8: c.269G>A Chromosome 6:151808181 A Chromosome 6:151808208 T Chromosome 6:151842622 0.01
rs779180038 C/T C ENST00000206249.8: c.727C>T Chromosome 6:151880738 A Chromosome 6:151880739 < 0.01
ESR1: Estrogen Receptor 1, GREB1: Growth Regulation by Estrogen in Breast Cancer 1 Like, HGVS: Human Genome Variation Society, MAF: Minor allele frequencies, rs
ID: Reference SNP identification number, SNP: Single Nucleotide Polymorphism
DISEASES database (JensenLab) revealed that both ESR1 and
GREB1 are strongly linked to a variety of hormone-dependent
and estrogen-responsive conditions. ESR1 showed high-
confidence associations with several diseases, most notably
breast cancer (Z: 9.0), carcinoma (Z: 7.4), endometriosis (Z:
7.1), and ovarian cancer (Z: 6.6). These associations reflect
ESR1’s pivotal role in estrogen signaling, transcriptional
regulation, and reproductive tissue homeostasis.
Similarly, GREB1—a gene regulated by ESR1 and known
to mediate estrogen-stimulated cell proliferation—also
demonstrated associations with estrogen-sensitive
pathologies. The strongest connections were observed with
breast cancer (Z: 5.3), endometriosis (Z: 4.7), amelogenesis
imperfecta type 1G (Z: 4.6); and various gynecologic
malignancies such as uterine cancer, ovarian cancer, and
uterine fibroids (Figures 2 and 3).
Collectively, these findings reinforce the functional
interplay between ESR1 and GREB1 in estrogen-regulated
pathways and highlight their shared involvement in the
pathogenesis of endometriosis and other hormone-related
disorders.
Figure 4 shows the representation of the estrogen
signaling pathway based on the KEGG pathway map. The
pathway includes both membrane-initiated and nuclear-
initiated steroid signaling mechanisms. ESR1 acts as a
central transcription factor activated by estrogen, leading to
downstream signaling events including activation of MAPK/
ERK and PI3K/AKT pathways. GREB1, indicated as a target
gene, is transcriptionally regulated by ESR1 upon estrogen
binding, suggesting its role as a downstream effector in
estrogen-dependent biological processes such as cell
proliferation, differentiation, and survival.
Figure 1. The PPI analysis was conducted using the STRING database (v11.5) and further supported by GeneMANIA (v3.5.2)
CYP19A1: Cytochrome P450 Family 19 Subfamily A Member 1, ESR1: Estrogen Receptor 1, GeneMANIA: Gene Multiple Association Network Integration, GREB1:
Growth Regulation by Estrogen in Breast Cancer 1, GREB1L: Growth Regulation by Estrogen in Breast Cancer 1 Like, NCOA1: Nuclear Receptor Coactivator 1, PGR:
Progesterone receptor, POLR2A: RNA Polymerase II Subunit A, PPI: Protein-protein interaction, SPDEF: SAM Pointed Domain Containing ETS Transcription Factor,
STC2: Stanniocalcin 2 STRING: Search Tool for the Retrieval of Interacting Genes/Proteins, TFF1: Trefoil Factor 1
Özbey and Kırkık. ESR1 and GREB1 Variants in Endometriosis
Discussion
In this study, a comprehensive in silico analysis was
performed to investigate the potential contribution of
missense SNPs in the ESR1 and GREB1 genes to the
pathogenesis of endometriosis. These genes were selected
due to their critical roles in estrogen signaling, cell
proliferation, and reproductive tissue regulation, all of
which are highly relevant to the etiology of endometriosis
(7-11). By integrating data from multiple bioinformatics
platforms—including SNP prediction tools, PPI networks,
and disease association databases—we sought to identify
high-risk variants that may influence disease susceptibility
and progression.
Our PPI analysis revealed that ESR1 serves as a central
hub within the estrogen signaling network, demonstrating
strong associations with GREB1 and other key genes such
as PGR, CYP1B1, and CTNNB1 (14,15). These interactions
support previous findings that ESR1 and GREB1 are not only
co-expressed but also functionally interlinked in hormone-
responsive pathways (8,10,11).
Further connections between ESR1 and components
of the RNA polymerase II complex (including POLR2A,
POLR2F, POLR2J, among others) emphasize its role in the
transcriptional activation of downstream target genes.
Additionally, interactions with genes such as CYP1B1,
TFF1, CTNNB1, and SAFB reflect ESR1’s broad involvement
in cellular processes including hormone metabolism, cell
Özbey and Kırkık. ESR1 and GREB1 Variants in Endometriosis
Figure 2. Disease association of ESR1 based on text mining analysis from the DISEASES database
ESR1: Estrogen Receptor 1
Figure 3. Disease association of GREB1 based on DISEASES database text mining
GREB1: Growth Regulation by Estrogen in Breast Cancer 1 Like
proliferation, and chromatin remodeling (14,16). In addition
to the molecular pathway relevance of these genes, the
clinical significance of the identified variants was also
examined. T o further contextualize the relevance of the
identified SNPs, we explored existing literature and variant
databases to determine whether these polymorphisms have
previously been associated with endometriosis or other
estrogen-dependent conditions. While none of the ESR1 or
GREB1 variants listed in Table 1 has been directly linked
to endometriosis in large genome-wide association studies,
some—such as ESR1 rs753014570 (c.728G>A)—have been
implicated in hormone-responsive cancers including breast
and ovarian cancer, where dysregulated estrogen signaling
is a common pathological feature (19,20). This overlap
is noteworthy, given the shared molecular mechanisms
between these diseases and endometriosis, including
estrogen-driven proliferation, progesterone resistance, and
inflammatory microenvironment remodeling. Additionally,
the low-frequency variants identified in ESR1 (e.g.,
rs779180038, rs746521050) may represent rare, potentially
functional mutations that could alter receptor conformation,
DNA binding affinity, or cofactor recruitment, ultimately
influencing downstream gene transcription. Although the
GREB1 variants identified in this study are intronic and
have not been directly associated with endometriosis, prior
evidence suggests that regulatory SNPs in intronic regions
can affect gene expression via splicing efficiency, enhancer
disruption, or transcription factor binding site modulation
(21,22). Therefore, these variants may contribute to altered
GREB1 expression levels in estrogen-responsive tissues.
Future experimental validation and population-based
association studies are required to assess the biological
significance of these candidate variants in endometriosis
pathogenesis (23,24). The functional link between ESR1 and
Özbey and Kırkık. ESR1 and GREB1 Variants in Endometriosis
Figure 4. Estrogen signaling pathway showing ESR1 activation and downstream regulation of GREB1 (adapted from KEGG)
ESR1: Estrogen Receptor 1, GREB1L: Growth Regulation by Estrogen in Breast Cancer 1 Like, KEGG: Kyoto Encyclopedia of Genes and Genomes
GREB1, in particular, underscores a shared role in estrogen-
mediated gene expression, suggesting that genetic variants
affecting these proteins may contribute to the molecular
pathology of endometriosis (10,11). The rationale for
selecting ESR1 and GREB1 in this study stems from their
well-established roles in estrogen signaling, which is central
to the pathogenesis of endometriosis (25,26). ESR1 encodes
Estrogen Receptor α (ERα), a nuclear hormone receptor that
regulates the transcription of estrogen-responsive genes
upon ligand binding (27,28). GREB1 is one such early response
gene directly upregulated by ESR1 via estrogen-bound
ERα complexes (29). Multiple studies have demonstrated
that GREB1 expression is tightly correlated with estrogen
stimulation in hormone-responsive tissues including the
endometrium and that it functions as a key mediator of
estrogen-driven cellular proliferation and differentiation
(30-32). Specifically, chromatin immunoprecipitation assays
have shown that ER α binds to enhancer regions within
the GREB1 gene locus, activating its transcription (33).
This regulatory axis is critical in endometrial biology, as
dysregulation of estrogen signaling is known to promote
the ectopic growth and invasiveness characteristic of
endometriotic lesions. Therefore, the functional interplay
between ESR1 and GREB1 reflects a direct transcriptional
hierarchy, wherein polymorphisms in either gene may
disrupt normal hormonal responses, leading to altered
gene expression patterns that favor the development or
persistence of endometriosis (8-34,35).
Several missense mutations in both ESR1 and GREB1 were
identified, some of which were predicted to be deleterious
across multiple algorithms. Variants such as rs779180038
and rs753014570, although classified as multi-nucleotide
variants with ambiguous impact, highlight the complexity
of interpreting in silico predictions and the necessity for
future experimental validation. These findings suggest
that specific SNPs may alter protein structure or function,
potentially disrupting ER activity or its downstream gene
targets (12-13).
Pathway and disease enrichment analyses supported
these observations, linking ESR1 and GREB1 not only to
endometriosis but also to other estrogen-dependent
conditions such as breast cancer, ovarian cancer, and uterine
fibroids (16,17). These overlapping associations underline
the shared molecular mechanisms underlying these
diseases and reinforce the importance of studying ESR1 and
GREB1 in a broader hormonal context (7-9).
Collectively, our results emphasize the value of
integrated bioinformatics approaches in identifying
candidate variants for further investigation. While in
silico predictions provide important insights, they should
be followed by functional assays and population-based
studies to validate the clinical relevance of the identified
mutations. Understanding how these genes and their
variants contribute to estrogen signaling and endometrial
pathophysiology may ultimately aid in the development of
more personalized diagnostic and therapeutic strategies for
endometriosis.
Conclusion
Although silico -based approaches cannot fully replace
experimental validation, they serve as valuable tools
for prioritizing candidate variants for further functional
and clinical research. The integration of these results
with future laboratory and population-level studies may
enhance our understanding of endometriosis and facilitate
the development of targeted diagnostic and therapeutic
strategies.
Ethics
Ethics Committee Approval: Since this study was entirely
based on publicly available bioinformatics databases and
performed using in silico analyses, no ethical approval was
required.
Informed Consent: As no human participants or patient
data were involved in this in silico study, informed consent
was not applicable.
Footnotes
Authorship Contributions
Surgical and Medical Practices: G.Ö., D.K., Concept: G.Ö.,
D.K., Design: G.Ö., D.K., Data Collection or Processing: G.Ö.,
D.K., Analysis or Interpretation: G.Ö., Literature Search: G.Ö.,
D.K., Writing: G.Ö., D.K.
Conflict of Interest: No conflict of interest was declared
by the authors.
Financial Disclosure: The authors declared that this
study received no financial support.
References
1. Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al.
Endometriosis. Endocr Rev. 2019;40:1048-1079. [Crossref]
2. Tsamantioti ES, Mahdy H. Endometriosis. In: StatPearls. Treasure Island
(FL): StatPearls Publishing; 2023. [Crossref]
3. Campagnacci R, Perretta S, Guerrieri M, Paganini AM, De Sanctis A,
Ciavattini A, et al. Laparoscopic colorectal resection for endometriosis.
Surg Endosc. 2005;19:662-664. [Crossref]
4. Hansen KA, Eyster KM. Genetics and genomics of endometriosis. Clin
Obstet Gynecol. 2010;53:403-412. [Crossref]
5. Nezhat C, Agarwal S, Lee DA, Tavallaee M. Can we accurately diagnose
endometriosis without a diagnostic laparoscopy? J Turk Ger Gynecol Assoc.
2022;23:117-119. [Crossref]
Özbey and Kırkık. ESR1 and GREB1 Variants in Endometriosis
6. Throwba H PK, Unnikrishnan L, Pangath M, Vasudevan K, Jayaraman S, Li
M, et al. The epigenetic correlation among ovarian cancer, endometriosis
and PCOS: A review. Crit Rev Oncol Hematol. 2022;180:103852. [Crossref]
7. Rumph JT, Stephens VR, Archibong AE, Osteen KG, Bruner-Tran KL.
Environmental endocrine disruptors and endometriosis. Adv Anat Embryol
Cell Biol. 2020;232:57-78. [Crossref]
8. Marla S, Mortlock S, Houshdaran S, Fung J, McKinnon B, Holdsworth-
Carson SJ, et al. Genetic risk factors for endometriosis near estrogen
receptor 1 and coexpression of genes in this region in endometrium. Mol
Hum Reprod. 2021;27:gaaa082. [Crossref]
9. Gaillard S, Bayable A, Deshmukh SK, Nayar U, Xiu J, Ingram L, et al.
Characterization of ESR1 mutations in endometrial and ovarian cancers. J
Clin Oncol. 2024;42:5598-5598. [Crossref]
10. Chadchan SB, Popli P , Liao Z, Andreas E, Dias M, Wang T, et al. A GREB1-
steroid receptor feedforward mechanism governs differential GREB1
action in endometrial function and endometriosis. Nat Commun.
2024;15:1947. [Crossref]
11. Fung JN, Holdsworth-Carson SJ, Sapkota Y, Zhao ZZ, Jones L, Girling JE, et al.
Functional evaluation of genetic variants associated with endometriosis
near GREB1. Hum Reprod. 2015;30:1263-1275. [Crossref]
12. National Center for Biotechnology Information [Internet]. Accessed 2025
Feb 1. [Crossref]
13. National Center for Biotechnology Information. dbSNP database [Internet].
Accessed 2025 Feb 1. [Crossref]
14. STRING: functional protein association networks [Internet]. Accessed
2025 Feb 9. [Crossref]
15. GeneMANIA: functional association networks [Internet]. Accessed 2025
Feb 9. [Crossref]
16. Kyoto Encyclopedia of Genes and Genomes (KEGG) [Internet]. Accessed
2025 Feb 9. [Crossref]
17. Kyoto Encyclopedia of Genes and Genomes (KEGG), KEGG Mapping
[Internet]. Accessed 2025 Feb 10. [Crossref]
18. DISEASES: Disease-gene associations database [Internet]. Accessed 2025
Feb 9. [Crossref]
19. Proestling K, Schreiber M, Miedl H, Hudson QJ, Husslein H, Kuessel L, et al.
The rs2046210 polymorphism is associated with endometriosis risk and
elevated estrogen receptor 1 expression in the eutopic endometrium of
women with the disease. Biomedicines. 2024;12:1657. [Crossref]
20. Genomic Data Commons Data Portal [Internet]. Accessed 2025 Feb 10.
[Crossref]
21. Deiana D, Gessa S, Anardu M, Daniilidis A, Nappi L, D’Alterio MN, et al.
Genetics of endometriosis: a comprehensive review. Gynecol Endocrinol.
2019;35:553-558. [Crossref]
22. Mortlock S, Corona RI, Kho PF, Pharoah P , Seo JH, Freedman ML, et al. A multi-
level investigation of the genetic relationship between endometriosis and
ovarian cancer histotypes. Cell Rep Med. 2022;3:100542. [Crossref]
23. Sapkota Y, Vivo I, Steinthorsdottir V, Fassbender A, Bowdler L, Buring JE, et
al. Analysis of potential protein-modifying variants in 9000 endometriosis
patients and 150000 controls of European ancestry. Sci Rep. 2017;7:11380.
[Crossref]
24. Rahmioglu N, Nyholt DR, Morris AP , Missmer SA, Montgomery GW,
Zondervan KT. Genetic variants underlying risk of endometriosis: insights
from meta-analysis of eight genome-wide association and replication
datasets. Hum Reprod Update. 2014;20:702-716. [Crossref]
25. Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al.
Endometriosis. Endocr Rev. 2019;40:1048-1079. [Crossref]
26. Marquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and estrogen
signaling in the endometrium: what goes wrong in endometriosis? Int J
Mol Sci. 2019;20:3822. [Crossref]
27. National Center for Biotechnology Information. ESR1 estrogen receptor 1
[Homo sapiens (human)] [Internet]. Accessed 2025 Feb 9. [Crossref]
28. Yaşar P , Ayaz G, User SD, Güpür G, Muyan M. Molecular mechanism of
estrogen-estrogen receptor signaling. Reprod Med Biol. 2016;16:4-20.
[Crossref]
29. Camden AJ, Szwarc MM, Chadchan SB, DeMayo FJ, O’Malley BW, Lydon JP ,
et al. Growth regulation by estrogen in breast cancer 1 (GREB1) is a novel
progesterone-responsive gene required for human endometrial stromal
decidualization. Mol Hum Reprod. 2017;23:646-653. [Crossref]
30. Cheng M, Michalski S, Kommagani R. Role for Growth Regulation by
Estrogen in Breast Cancer 1 (GREB1) in hormone-dependent cancers. Int J
Mol Sci. 2018;19:2543. [Crossref]
31. Hodgkinson K, Forrest LA, Vuong N, Garson K, Djordjevic B, Vanderhyden
BC. GREB1 is an estrogen receptor-regulated tumour promoter that is
frequently expressed in ovarian cancer. Oncogene. 2018;37:5873-5886.
[Crossref]
32. Maccio L, Arciuolo D, Santoro A, Raffone A, Raimondo D, Ronchi S, et al.
Clinicopathological comparison between GREB1- and ESR1-Rearranged
Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCTs): A
Systematic Review. Diagnostics. 2025;15:792. [Crossref]
33. Hou TY, Kraus WL. Analysis of estrogen-regulated enhancer RNAs
identifies a functional motif required for enhancer assembly and gene
expression. Cell Rep. 2022;39:110944. [Crossref]
34. Pellegrini C, Gori I, Achtari C, Hornung D, Chardonnens E, Wunder D, et al.
The expression of estrogen receptors as well as GREB1, c-MYC, and cyclin
D1, estrogen-regulated genes implicated in proliferation, is increased in
peritoneal endometriosis. Fertil Steril. 2012;98:1200-1208. [Crossref]
35. Chadchan SB, Popli P , Liao Z, Andreas E, Dias M, Wang T, et al. A GREB1-
steroid receptor feedforward mechanism governs differential GREB1
action in endometrial function and endometriosis. Nat Commun.
2024;15:1947. [Crossref]
Özbey and Kırkık. ESR1 and GREB1 Variants in Endometriosis
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.